Current Science

Open Access Open Access  Restricted Access Subscription Access

Quality Assurance of Rituximab (Anti-CD 20) Antibodies by Potency Testing:Determining the System Suitability Criteria and Sample Acceptance Criteria


Affiliations
1 National Institute of Biologicals (Ministry of Health and Family Welfare), Government of India, Plot No. A-32, Sector-62, Institutional Area, Noida 201 309, India
 

A validated and robust bioassay is of paramount importance in the various stages of biosimilar development to ensure efficacy, quality and potency. The complement-dependent cytotoxicity assay was validated over six simulated potencies and found specific for rituximab-like antibodies. The bioassay was found robust with linearity parameter R2 = 0.99, %GCV for precision and accuracy was less than 20% for >40 individual performances. Detailed set of system suitability and sample acceptance criteria was determined. The study may play a key part in the development of written and physical potency reference standards for incorporation in different pharmacopeia for effective biosimilar development and regulation.

Keywords

Complement-Dependent Cytotoxicity, Geometric Coefficient of Variation, Quality Assurance, Rituximab.
User
Notifications
Font Size

  • Li, E., Subramanian, J., Anderson, S., Thomas, D., McKinley, J. and Jacobs, I. A., Development of biosimilars in an era of oncologic drug shortages. Drug Des. Dev. Ther., 2015, 9, 3247–3255.

  • Cronstein, B. N., The benefits and drawbacks of biosimilars. Clin. Adv. Hematol. Oncol., 2015, 13(10), 639–641.

  • Jacobs, I., Ewesuedo, R., Lula, S. and Zacharchuk, C., Biosimilars for the treatment of cancer: a systematic review of published evidence. Biodrugs, 2017, 31(1), 1–36.

  • Misra, M., Biosimilars: current perspectives and future implications. Indian J. Pharmacol., 2014, 44(1), 12–14.

  • USFDA, FDA guidance: guidance for industry, bioanalytical method validation. US Food and Drug Administration, 2013

  • Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, European Medicines Agency, 2014.

  • CDSCO, Guidelines on similar biologics: regulatory requirements for marketing authorization in India, Central Drugs Standard Control Organization, New Delhi, 2016.

  • Gurcan, H. M., Keskin, D.B., Stern, J. N., Nitzberg, M. A., Shekhani, H. and Ahmed, A. R., A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol., 2009, 9(1), 10–25.

  • Smith, M. R., Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 2003, 22, 7359–7368.

  • Clatworthy, M. R., Targeting B cells and antibody in transplantation. Am. J. Transplant., 2011, 11(7), 1359–1367.

  • Weiner, G. J., Rituximab: mechanism of action. Semin. Hematol., 2010, 47(2), 115–123.

  • Boross, P. and Leusen, J. H. W., Mechanisms of action of CD20 antibodies. Am. J. Cancer. Res., 2012, 2(6), 676–690.

  • Harjunpaa, A., Junnikkala, S. and Meri, S., Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol., 2000, 51, 634–641.

  • USP/MC; Rituximab Summary Validation Report, Report, USP Medicines Compendium, 2013.

  • Reed, G. F., Lynn, F. and Meade, B. D., Use of coefficient of variation in assessing variability of quantitative assays. Clin. Diagn. Lab. Immunol., 2002, 9(6), 1235–1239.

  • Biological Assay Validation. United States Pharmacopoeia, 35–NF 30, 2012.

  • Dafale, N., Semwal, U., Agarwal, P., Sharma, P. and Singh, G., Development and validation of microbial bioassay for quantification of levofloxacin in pharmaceutical preparations. J. Pharm. Anal., 2015, 5(1), 18–26.

  • Coffey, T, Grevenkamp, M., Wilson, A. and Hu, M., Biological assay qualification using design of experiments. Bioprocess. Int., 2013, 11(6), 42–49.

  • Tsiftsoglou, A. S., Ruiz. S. and Schneider, C. K., Development and regulation of biosimilars: current status and future challenges. BioDrugs., 2013, 27(3), 203–211.

  • ICH harmonised tripartite guideline, ‘Validation on analytical procedures: text and (methodology)’, International Council for Harmonisation, Q2 (R1), Step 4, 2005.

  • Design and development of biological assays, United States Pharmacopoeia, 35–NF 30, 2012.


Abstract Views: 282

PDF Views: 95




  • Quality Assurance of Rituximab (Anti-CD 20) Antibodies by Potency Testing:Determining the System Suitability Criteria and Sample Acceptance Criteria

Abstract Views: 282  |  PDF Views: 95

Authors

Subhash Chand
National Institute of Biologicals (Ministry of Health and Family Welfare), Government of India, Plot No. A-32, Sector-62, Institutional Area, Noida 201 309, India
Birendra Kumar
National Institute of Biologicals (Ministry of Health and Family Welfare), Government of India, Plot No. A-32, Sector-62, Institutional Area, Noida 201 309, India
Vivek Morris Prathap
National Institute of Biologicals (Ministry of Health and Family Welfare), Government of India, Plot No. A-32, Sector-62, Institutional Area, Noida 201 309, India
Surinder Singh
National Institute of Biologicals (Ministry of Health and Family Welfare), Government of India, Plot No. A-32, Sector-62, Institutional Area, Noida 201 309, India
Richi V. Mahajan
National Institute of Biologicals (Ministry of Health and Family Welfare), Government of India, Plot No. A-32, Sector-62, Institutional Area, Noida 201 309, India

Abstract


A validated and robust bioassay is of paramount importance in the various stages of biosimilar development to ensure efficacy, quality and potency. The complement-dependent cytotoxicity assay was validated over six simulated potencies and found specific for rituximab-like antibodies. The bioassay was found robust with linearity parameter R2 = 0.99, %GCV for precision and accuracy was less than 20% for >40 individual performances. Detailed set of system suitability and sample acceptance criteria was determined. The study may play a key part in the development of written and physical potency reference standards for incorporation in different pharmacopeia for effective biosimilar development and regulation.

Keywords


Complement-Dependent Cytotoxicity, Geometric Coefficient of Variation, Quality Assurance, Rituximab.

References





DOI: https://doi.org/10.18520/cs%2Fv114%2Fi12%2F2513-2518